Hemodialysis patients (ESRD). End-stage renal disease
Conditions
Interventions
Intervention 1: Placebo administered as tablets to control group for two months. Intervention 2: Oral Nicotinamide is administered to intervention group for 8 weeks: 500 mg daily in two doses for firs
Placebo
Placebo administered as tablets to control group for two months.
Oral Nicotinamide is administered to intervention group for 8 weeks: 500 mg daily in two doses for first 4 weeks and 1000 mg daily in two doses for the second four weeks.
Sponsors
Ahvaz Jondishapour University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age>18 years old, hemodialysis for more than 3 months, constant use of phosphate binder in recent two weeks, serum phosphorus>=5 Exclusion Criteria: liver disease or significant disturbance in liver function tests, active peptic ulcer, poor cooperation, severe diarrhea
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum phosphorus. Timepoint: week 0, 5 and 9 of the study. Method of measurement: serum phosphorus measurement by biochemistry autoanalyser. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum iPTH. Timepoint: before and after the intervention. Method of measurement: Chemiluminescence iPTH measurement.;Serum lipids. Timepoint: before and after the intervention. Method of measurement: serum biochemistry by autoanalyser. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Azita Zafar Mohtashami
Golestan Hospital - Ahvaz University of Medical sciences
Outcome results
None listed